Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

GS-PI-1 is a promising new generation HIV PI with favorable potency and resistance barrier

March 2, 2017

ViiV Healthcare patents HIV integrase inhibitors

Feb. 27, 2017

ViiV Healthcare UK identifies novel HIV integrase inhibitors

Feb. 24, 2017

UB-421 monotherapy shows promise for HAART substitution

Feb. 23, 2017

Gilead tests novel non-catalytic site integrase inhibitor GS-9822 in vivo

Feb. 22, 2017

Neurocognitive effects of cenicriviroc assessed in phase II study

Feb. 21, 2017

Novel HIV capsid inhibitors created at Gilead

Feb. 21, 2017

High virologic response rates seen with bictegravir regimen in phase II trial

Feb. 17, 2017

Hetero Research Foundation patents antiviral agents

Feb. 16, 2017

Phase III data show non-inferiority of doravirine and darunavir/ritonavir

Feb. 16, 2017

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...